MJP6412
Based on 1 Customer Validation
MJP6412 is a p300 and CBP PROTAC degrader that potently degrades p300 and CBP in 22Rv1 cells with DC50 values of 1.6 nM and 1.2 nM, respectively. MJP6412 downregulates the expression of AR-FL, AR-V7 and c-MYC, as well as androgen receptor target genes (KLK3, FKBP5, TMPRSS2). MJP6412 completely abolishes p300/CBP-dependent histone acetylation (H3K27Ac and H2BNTAC) and induces G1 cell cycle arrest. MJP6412 inhibits cancer cell proliferation and tumor growth. MJP6412 can be used in prostate cancer-related research.
(Pink: CBP/p300 ligand (HY-111784); Blue: Cereblon ligand (HY-W087383); Black: linker (HY-W102095)).
For research use only. We do not sell to patients.
- Purity : 95.90%
- CAS No.: 3105406-14-9
- Formula: C55H54F2N8O9
- Molecular Weight:1009.06
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
p300 |
CBP |
AR-FL |
AR-V7 |
KLK3 |
FKBP5 |
TMPRSS2 |
In Vitro
MJP6412 (0.1-1000 nM; 24 h) potently degrades p300 (DC50 = 1.6 nM, Dmax = 96%) and CBP (DC50 = 1.2 nM, Dmax = 89%) in 22Rv1 human castration-resistant prostate cancer cells after 24 h of treatment[1].
MJP6412 (5 days) potently inhibits the growth of 22Rv1 human castration-resistant prostate cancer cells with an IC50 of 37.6 nM and Imax of 91% after 5 days of treatment[1].
MJP6412 (0.1-1000 nM; 24 h) potently degrades p300 (DC50 = 3.4 nM, Dmax = 94%) and CBP (DC50 = 3.7 nM, Dmax = 82%) in LNCaP human prostate cancer cells after 24 h of treatment[1].
MJP6412 (0.1-1000 nM; 24 h) potently degrades p300 (DC50 = 1.6 nM, Dmax = 97%) and CBP (DC50 = 1.4 nM, Dmax = 89%) in VCaP human prostate cancer cells after 24 h of treatment[1].
MJP6412 (10 nM; 12 h) degrades p300 and CBP in 22Rv1 human castration-resistant prostate cancer cells via a ubiquitin-proteasome-dependent PROTAC mechanism that requires CRBN recruitment and binding to p300/CBP[1].
MJP6412 (100 nM; 6 h) acts as a highly selective p300/CBP degrader in 22Rv1 human castration-resistant prostate cancer cells, with no reduction in known CRBN neo-substrates after 6 h of treatment with 100 nM[1].
MJP6412 (5 days) potently inhibits the growth of VCaP human prostate cancer cells with an IC50 of 7.9 nM and Imax of 98% after 5 days of treatment[1].
MJP6412 (5 days) potently inhibits the growth of LNCaP human prostate cancer cells with an IC50 of 21.4 nM and Imax of 89% after 5 days of treatment[1].
MJP6412 (5 days) potently inhibits the growth of enzalutamide-resistant VCaP-ENR human prostate cancer cells with an IC50 of 5.2 nM and Imax of 98% after 5 days of treatment[1].
MJP6412 (5 days) potently inhibits the growth of enzalutamide-resistant LNCaP-ENR human prostate cancer cells with an IC50 of 138.1 nM and Imax of 72% after 5 days of treatment[1].
MJP6412 (10-100 nM; 24-48 h) downregulates AR and c-MYC signaling in 22Rv1 human castration-resistant prostate cancer cells, reducing AR-FL, AR-V7, and c-MYC protein and mRNA levels, as well as AR-regulated gene mRNA levels, after 24−48 h of treatment with 10−100 nM[1].
MJP6412 (10-100 nM; 12 h) completely extinguishes p300/CBP-dependent histone acetylation (H3K27Ac, H2BK5Ac, H2BK20Ac) in 22Rv1 human castration-resistant prostate cancer cells after 12 h of treatment with 100 nM[1].
MJP6412 (10 nM; 0.25-96 h) induces long-lasting degradation of p300 and CBP in 22Rv1 human castration-resistant prostate cancer cells, with maximum degradation starting at 12 h and lasting through 48 h after treatment with 10 nM[1].
MJP6412 (1-100 nM; 48 h) induces dose-dependent G1 cell cycle arrest in VCaP human prostate cancer cells, with significant arrest occurring after 48 h of treatment with 100 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:VCaP human prostate cancer cells
-
Concentration:1, 10 and 100 nM
-
Incubation Time:48 h
-
Result:Induced G1 cell cycle arrest in a dose-dependent manner.
Induced detectable G1 arrest at 1 nM.
Significantly induced G1 arrest at 100 nM.
-
Cell Line:VCaP cells
-
Concentration:0.1, 1, 10 and 100 nM
-
Incubation Time:24 h (for AR-FL, AR-V7, and c-MYC protein expression); 12 h (for H2BK5Ac, H2BK20Ac, and H3K27Ac protein expression)
-
Result:Treatment with 0.1, 1, 10, and 100 nM for 24 h resulted in a dose-dependent decrease in AR-FL, AR-V7, and c-MYC protein expression.
At 10 nM, the expression of AR-FL and AR-V7 was significantly reduced, and at 100 nM, a >80% reduction in AR-FL and AR-V7 proteins was observed.
For c-MYC, 10 nM significantly reduced its expression, and 100 nM almost completely depleted it.
In the acetylation assay, treatment with 10 nM for 12 h significantly decreased the levels of H3K27Ac, H2BK5Ac, and H2BK20Ac, and these acetylation marks were almost completely abolished at 100 nM.
Parmacokinetics
| Species | Dose | Route | T1/2 | AUC0-t | Vz | CL | MRT0-t |
|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.v. | 4.27 h | 2407 ng/mL·h | 12500 mL/kg | 2058 mL/h/kg | 2.75 h |
In Vivo
MJP6412 (3-15 mg/kg; i.v.; every other day; 24 days) exhibits significant antitumor activity with a 42% TGI in VCaP prostate cancer xenograft tumors in BALB/c-Nude mice, with excellent biosafety[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice 22Rv1 prostate cancer xenograft[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced p300 protein levels in 22Rv1 xenograft tumor tissue at 6 hours post-treatment.
-
Animal Model:Male BALB/c-Nude mice, 6 weeks old, were maintained in a standard SPF mouse room. VCaP cells (1 × 10⁷ cells in Matrigel (Corning Life Sciences), 0.2 mL/mouse) were injected subcutaneously into the right side of the induced cell-derived xenograft tumor and allowed to grow to the indicated size. When the average volume of the tumors reached approximately 200 mm³, treatment can start.
[1] -
Dosage:3 mg/kg; 15 mg/kg
-
Administration:i.v.; every other day; 24 days
-
Result:Achieved a tumor growth inhibition (TGI) value of 42% at 15 mg/kg, comparable to positive control CCS1477.
Was well tolerated, with no significant mouse weight loss observed over the 24-day treatment period.
Chemical Information
-
CAS No. 3105406-14-9
-
Appearance Solid
-
Molecular Weight 1009.06
-
Formula C55H54F2N8O9
-
Color Light yellow to yellow
-
SMILES
O=C(CCC1N(C(C2=C3C=CC(N4CCC(CC4)OC5=CC=C(C=C5)NC(CO[C@H]6CC[C@H](N7C([C@H]8N(C9=CC(F)=C(F)C=C9)C(CCC8)=O)=NC%10=CC(C%11=C(C)ON=C%11C)=CC=C7%10)CC6)=O)=C2)=O)C3=O)NC1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (99.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.48 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9910 mL | 4.9551 mL | 9.9102 mL | 24.7755 mL |
| 5 mM | 0.1982 mL | 0.9910 mL | 1.9820 mL | 4.9551 mL | |
| 10 mM | 0.0991 mL | 0.4955 mL | 0.9910 mL | 2.4776 mL | |
| 15 mM | 0.0661 mL | 0.3303 mL | 0.6607 mL | 1.6517 mL | |
| 20 mM | 0.0496 mL | 0.2478 mL | 0.4955 mL | 1.2388 mL | |
| 25 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.9910 mL | |
| 30 mM | 0.0330 mL | 0.1652 mL | 0.3303 mL | 0.8259 mL | |
| 40 mM | 0.0248 mL | 0.1239 mL | 0.2478 mL | 0.6194 mL | |
| 50 mM | 0.0198 mL | 0.0991 mL | 0.1982 mL | 0.4955 mL | |
| 60 mM | 0.0165 mL | 0.0826 mL | 0.1652 mL | 0.4129 mL | |
| 80 mM | 0.0124 mL | 0.0619 mL | 0.1239 mL | 0.3097 mL |
Keywords
- MJP6412
- 3105406-14-9
- MJP 6412
- MJP-6412
- PROTACs
- Histone Acetyltransferase
- c-Myc
- Androgen Receptor
- CRBN
- p300
- LNCaP human prostate cancer cells
- ubiquitin proteasome system
- enzalutamide-resistant prostate cancer
- CBP
- androgen receptor
- VCaP human prostate cancer cells
- xenograft model
- 22Rv1 human castration-resistant prostate cancer cells
- Inhibitor
- inhibitor
- inhibit